Jennifer Zavala
Nurse Practitioner · San Antonio, TXNPI 1184904336
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $12,040 of the $17,197 with a category attached, or 70.0%. 38 manufacturers reported payments, led by UCB, Inc. at 24.2% of the total. Among nurse practitioner clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 524 payments — averaging $32.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB, Inc.$4K
- AstraZeneca$3K
- Amgen$2K
- Johnson & Johnson$2K
- Novartis$1K
- Mallinckrodt Hospital Products Inc.$894
- plus $4K from 32 others
What the payments were for
- Consulting fees$3,67021%
- Speaking & faculty fees$2501%
- Travel & lodging$1,1166%
- Food & beverage$12,04070%
- Education$1211%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| UCB, Inc. | 35 | $4,168 |
| AstraZeneca | 26 | $2,524 |
| Amgen(2 entities) | 119 | $2,396 |
| Johnson & Johnson(2 entities) | 67 | $1,537 |
| Novartis | 65 | $1,436 |
| Mallinckrodt Hospital Products Inc. | 34 | $894 |
| Lilly USA, LLC | 38 | $789 |
| Boehringer Ingelheim | 8 | $369 |
| Pfizer | 20 | $310 |
| AbbVie | 2 | $300 |
| Radius Health, Inc. | 15 | $300 |
| Aurinia Pharma U.S., Inc. | 12 | $274 |
| Genentech USA, Inc. | 15 | $244 |
| E.r. Squibb & Sons, L.L.C. | 12 | $239 |
| ANI Pharmaceuticals, Inc. | 11 | $231 |
| Janssen Scientific Affairs, LLC | 2 | $225 |
| GSK | 8 | $202 |
| Pacira Therapeutics, Inc. | 6 | $140 |
| Actelion Pharmaceuticals US, Inc. | 2 | $74 |
| Inari Medical, Inc. | 2 | $73 |
| Fresenius Kabi USA, LLC | 3 | $65 |
| Ferring Pharmaceuticals Inc. | 4 | $62 |
| Sobi, Inc | 2 | $55 |
| Teva Pharmaceuticals USA, Inc. | 2 | $31 |
| Almatica Pharma LLC | 1 | $28 |
| Ultragenyx Pharmaceutical Inc. | 1 | $22 |
| Celltrion USA Inc. | 1 | $22 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $21 |
| Chiesi USA, Inc. | 1 | $21 |
| Octapharma USA, Inc. | 1 | $20 |
| Organon | 1 | $19 |
| Currax Pharmaceuticals LLC | 1 | $19 |
| Pacira Pharmaceuticals Incorporated | 1 | $17 |
| Intuitive Surgical | 1 | $15 |
| Merck | 1 | $14 |
| Boston Scientific | 1 | $14 |
| Shield Therapeutics Inc | 1 | $13 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$17,197 in reported general payments places this provider in the 95th percentile of 5,422 nurse practitioner providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OtezlaApremilast | 37 | $209,017 |
| Enbrel SureclickEtanercept | 13 | $96,610 |
| Hydroxychloroquine Sulfate | 398 | $12,225 |
| Leflunomide | 87 | $3,572 |
| MethotrexateMethotrexate Sodium | 140 | $2,562 |
| Gabapentin | 157 | $2,361 |
| Sulfasalazine | 83 | $2,116 |
| Cevimeline Hcl | 13 | $1,786 |
| Colchicine | 11 | $1,643 |
| Lidocaine | 12 | $1,536 |
| Doxycycline Hyclate | 39 | $1,424 |
| Prednisone | 131 | $1,010 |
| Methylprednisolone | 60 | $858 |
| Baclofen | 77 | $723 |
| Cyanocobalamin InjectionCyanocobalamin (Vitamin B-12) | 20 | $654 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenOtezla | $2,396 | $209,01737 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 5,422 nurse practitioner providers in Texas.
Other nurse practitioner in San Antonio
- Corrie BerkSan Antonio$155K
- Sonja BruneSan Antonio$51K
- Laura GalvanSan Antonio$32K
- Eduardo GonzalezSan Antonio$32K
- Roberta RomeroSan Antonio$26K
- Christopher GarciaSan Antonio$21K
- Amy RivasSan Antonio$17K
- Alexis WahlenSan Antonio$16K
- Cecilia DavisAustin$262K
- Melanie MorrisHouston$254K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.